FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313334428> ?p ?o ?g. }

• W4313334428 endingPage "14" @default.
• W4313334428 startingPage "3" @default.
• W4313334428 abstract "To describe patient characteristics, effectiveness and safety in a real-world population treated with niraparib in the Spanish expanded-access programme.This retrospective observational study included women with platinum-sensitive recurrent high-grade serous ovarian cancer who received maintenance niraparib within the Spanish niraparib expanded-access programme. Eligible patients had received ≥2 previous lines of platinum-containing therapy, remained platinum-sensitive after the penultimate line of platinum and had responded to the most recent platinum-containing therapy. Niraparib dosing was at the treating physician's discretion (300 mg/day fixed starting dose or individualised starting dose [ISD] according to baseline body weight and platelet count). Safety, impact of dose adjustments, patient characteristics and effectiveness were analysed using data extracted from medical records.Among 316 eligible patients, 80% had BRCA wild-type tumours and 66% received an ISD. Median niraparib duration was 7.8 months. The most common adverse events typically occurred within 3 months of starting niraparib. Median progression-free survival was 8.6 (95% confidence interval [CI] 7.6-10.0) months. One- and 2-year overall survival rates were 86% (95% CI 81-89%) and 65% (95% CI 59-70%), respectively. Dose interruptions, dose reductions, haematological toxicities and asthenia/fatigue were less common with ISD than fixed starting dose niraparib, but progression-free survival was similar irrespective of dosing strategy. Subsequent therapy included platinum in 71% of patients who received further treatment.Outcomes in this large real-world dataset of niraparib-treated patients are consistent with phase III trials, providing reassuring evidence of the tolerability and activity of niraparib maintenance therapy for platinum-sensitive recurrent ovarian cancer.NCT04546373." @default.
• W4313334428 created "2023-01-06" @default.
• W4313334428 creator A5000058797 @default.
• W4313334428 creator A5006164153 @default.
• W4313334428 creator A5007606531 @default.
• W4313334428 creator A5008353011 @default.
• W4313334428 creator A5008765868 @default.
• W4313334428 creator A5016345753 @default.
• W4313334428 creator A5023230423 @default.
• W4313334428 creator A5027996135 @default.
• W4313334428 creator A5033251451 @default.
• W4313334428 creator A5033961134 @default.
• W4313334428 creator A5034608715 @default.
• W4313334428 creator A5034722344 @default.
• W4313334428 creator A5035502806 @default.
• W4313334428 creator A5042084238 @default.
• W4313334428 creator A5046083398 @default.
• W4313334428 creator A5047341028 @default.
• W4313334428 creator A5047678330 @default.
• W4313334428 creator A5050023877 @default.
• W4313334428 creator A5065462750 @default.
• W4313334428 creator A5068038197 @default.
• W4313334428 creator A5071133089 @default.
• W4313334428 creator A5077901139 @default.
• W4313334428 creator A5082578314 @default.
• W4313334428 creator A5082612440 @default.
• W4313334428 creator A5082684040 @default.
• W4313334428 creator A5090906445 @default.
• W4313334428 date "2023-03-01" @default.
• W4313334428 modified "2023-10-14" @default.
• W4313334428 title "Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme" @default.
• W4313334428 cites W2130078242 @default.
• W4313334428 cites W2160466424 @default.
• W4313334428 cites W2528228811 @default.
• W4313334428 cites W2737389832 @default.
• W4313334428 cites W2754327139 @default.
• W4313334428 cites W2785391206 @default.
• W4313334428 cites W2804717005 @default.
• W4313334428 cites W2884001607 @default.
• W4313334428 cites W2897430921 @default.
• W4313334428 cites W2898518424 @default.
• W4313334428 cites W2908639608 @default.
• W4313334428 cites W2960245070 @default.
• W4313334428 cites W2972664697 @default.
• W4313334428 cites W2975141952 @default.
• W4313334428 cites W2976139792 @default.
• W4313334428 cites W2985426630 @default.
• W4313334428 cites W2994977341 @default.
• W4313334428 cites W3023274953 @default.
• W4313334428 cites W3042004834 @default.
• W4313334428 cites W3048967410 @default.
• W4313334428 cites W3049395940 @default.
• W4313334428 cites W3089254712 @default.
• W4313334428 cites W3120953566 @default.
• W4313334428 cites W3164955685 @default.
• W4313334428 cites W3210256176 @default.
• W4313334428 cites W3211294247 @default.
• W4313334428 cites W4224216021 @default.
• W4313334428 cites W4281666355 @default.
• W4313334428 cites W4281668006 @default.
• W4313334428 cites W4283079952 @default.
• W4313334428 cites W4295225748 @default.
• W4313334428 doi "https://doi.org/10.1016/j.ejca.2022.12.023" @default.
• W4313334428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36706655" @default.
• W4313334428 hasPublicationYear "2023" @default.
• W4313334428 type Work @default.
• W4313334428 citedByCount "1" @default.
• W4313334428 countsByYear W43133344282023 @default.
• W4313334428 crossrefType "journal-article" @default.
• W4313334428 hasAuthorship W4313334428A5000058797 @default.
• W4313334428 hasAuthorship W4313334428A5006164153 @default.
• W4313334428 hasAuthorship W4313334428A5007606531 @default.
• W4313334428 hasAuthorship W4313334428A5008353011 @default.
• W4313334428 hasAuthorship W4313334428A5008765868 @default.
• W4313334428 hasAuthorship W4313334428A5016345753 @default.
• W4313334428 hasAuthorship W4313334428A5023230423 @default.
• W4313334428 hasAuthorship W4313334428A5027996135 @default.
• W4313334428 hasAuthorship W4313334428A5033251451 @default.
• W4313334428 hasAuthorship W4313334428A5033961134 @default.
• W4313334428 hasAuthorship W4313334428A5034608715 @default.
• W4313334428 hasAuthorship W4313334428A5034722344 @default.
• W4313334428 hasAuthorship W4313334428A5035502806 @default.
• W4313334428 hasAuthorship W4313334428A5042084238 @default.
• W4313334428 hasAuthorship W4313334428A5046083398 @default.
• W4313334428 hasAuthorship W4313334428A5047341028 @default.
• W4313334428 hasAuthorship W4313334428A5047678330 @default.
• W4313334428 hasAuthorship W4313334428A5050023877 @default.
• W4313334428 hasAuthorship W4313334428A5065462750 @default.
• W4313334428 hasAuthorship W4313334428A5068038197 @default.
• W4313334428 hasAuthorship W4313334428A5071133089 @default.
• W4313334428 hasAuthorship W4313334428A5077901139 @default.
• W4313334428 hasAuthorship W4313334428A5082578314 @default.
• W4313334428 hasAuthorship W4313334428A5082612440 @default.
• W4313334428 hasAuthorship W4313334428A5082684040 @default.
• W4313334428 hasAuthorship W4313334428A5090906445 @default.
• W4313334428 hasBestOaLocation W43133344281 @default.
• W4313334428 hasConcept C121608353 @default.
• W4313334428 hasConcept C126322002 @default.

• next